At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CERO CERo Therapeutics Holdings, Inc.
Market Closed 09-11 16:00:00 EDT Delay
SRX Global Buys Senior Secured Debt in CERo Therapeutics Holdings
Reuters  ·  09-03
SRX Global Buys Senior Secured Debt in CERo Therapeutics Holdings
SRX Global Buys Senior Secured Debt in CERo Therapeutics Holdings
Reuters  ·  08-31
SRX Global Buys Senior Secured Debt in CERo Therapeutics Holdings
Srx Global Acquires Senior Secured Debt in Cero Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers
THOMSON REUTERS  ·  08-31
Srx Global Acquires Senior Secured Debt in Cero Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers
Srx Global - Investment Expected to Accelerate Cero Clinical Program Advancement
THOMSON REUTERS  ·  08-31
Srx Global - Investment Expected to Accelerate Cero Clinical Program Advancement
SRX Global Sells 3,579 Series C Preferred Shares in Private Placement Valued at $2.86 Million
Reuters  ·  08-29
SRX Global Sells 3,579 Series C Preferred Shares in Private Placement Valued at $2.86 Million
Cero Therapeutics Q2 FY26 Net Loss Narrows 81% to $1.03 Million; R&D Expenses Fall 37% to $1.74 Million
Reuters  ·  08-15
Cero Therapeutics Q2 FY26 Net Loss Narrows 81% to $1.03 Million; R&D Expenses Fall 37% to $1.74 Million
Ovid Therapeutics Names Kevin Norrett Chief Business Officer
Reuters  ·  07-08
Ovid Therapeutics Names Kevin Norrett Chief Business Officer
Cero Therapeutics Amends SRX Health Promissory Note, Lifts Borrowing Capacity to $1.41 Million
Reuters  ·  06-27
Cero Therapeutics Amends SRX Health Promissory Note, Lifts Borrowing Capacity to $1.41 Million
CERo Therapeutics says AML patient in CER-1236 Phase 1 trial proceeds to allogeneic stem cell transplant
Reuters  ·  06-15
CERo Therapeutics says AML patient in CER-1236 Phase 1 trial proceeds to allogeneic stem cell transplant
Cero Therapeutics Announces Clinical Update From Certain-T Phase 1 Cer-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment
THOMSON REUTERS  ·  06-15
Cero Therapeutics Announces Clinical Update From Certain-T Phase 1 Cer-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment
Cero Therapeutics issues USD 750,000 convertible note to SRX Health Solutions
Reuters  ·  05-30
Cero Therapeutics issues USD 750,000 convertible note to SRX Health Solutions
60 Degrees Pharma appoints Eric Francois to board
Reuters  ·  05-19
60 Degrees Pharma appoints Eric Francois to board
Cero Therapeutics Q1 FY26 net loss widens 15.3% to $5.9 million
Reuters  ·  05-16
Cero Therapeutics Q1 FY26 net loss widens 15.3% to $5.9 million
CERo Therapeutics escalates CER-1236 Phase 1 trial to 10 million cells/kg cohort
Reuters  ·  05-11
CERo Therapeutics escalates CER-1236 Phase 1 trial to 10 million cells/kg cohort
Cero Therapeutics Completes Second Ascending Dose Cohort of Phase 1 Cer-1236 Trial
THOMSON REUTERS  ·  05-11
Cero Therapeutics Completes Second Ascending Dose Cohort of Phase 1 Cer-1236 Trial
Cero Therapeutics Holdings Inc - No Dose-Limiting Toxicities Observed at 4 × 10⁶ Cells/Kg Dose in Second Cohort
THOMSON REUTERS  ·  05-11
Cero Therapeutics Holdings Inc - No Dose-Limiting Toxicities Observed at 4 × 10⁶ Cells/Kg Dose in Second Cohort
Cero Therapeutics enters USD 1 million convertible note facility with Keystone Capital Partners
Reuters  ·  05-02
Cero Therapeutics enters USD 1 million convertible note facility with Keystone Capital Partners
Cero Therapeutics director Francois Eric files initial beneficial ownership statement
Reuters  ·  04-22
Cero Therapeutics director Francois Eric files initial beneficial ownership statement
Cero Therapeutics FY25 net loss climbs 139.9% to $19.9 million
Reuters  ·  04-16
Cero Therapeutics FY25 net loss climbs 139.9% to $19.9 million
Cero Therapeutics sells $350,000 convertible note in private placement to Keystone Capital Partners
Reuters  ·  04-15
Cero Therapeutics sells $350,000 convertible note in private placement to Keystone Capital Partners

Introduction

Company Name.
CERo Therapeutics Holdings, Inc.
Affiliated Markets:
OTCQB
Listing Date:
--
Main Business:
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.
Issue price:
--